T regulatory cells lacking CD25 are increased in MS during relapse

References

• Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008; 28 6: 697–706.
   PubMedGoogle Scholar
• Toubi E. The role of CD4+CD25+T regulatory cells in autoimmune diseases. Clin Rev Allergy Immunol. 2008; 34 3: 338–344.
   PubMedGoogle Scholar
• Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000; 106 12: R75–R81.
   PubMed Web of Science ®Google Scholar
• Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001; 27 1: 18–20.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27 1: 20–21.
   PubMed Web of Science ®Google Scholar
• Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Maeda M, Onodera M, Uchiyama T, Fujii S, Sakaguchi S. Crucial role of FOXP3 in the development and function of human CD25+CD4+regulatory T cells. Int Immunol. 2004; 16 11: 1643–1656.
   PubMed Web of Science ®Google Scholar
• Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008; 112 6: 2340–2352.
   PubMed Web of Science ®Google Scholar
• Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol. 2008; 4 7: 384–398.
   PubMedGoogle Scholar
• Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009; 69 9: 3995–4000.
   PubMedGoogle Scholar
• Banham AH. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol. 2006; 27 12: 541–544.
   PubMedGoogle Scholar
• Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203 7: 1693–1700.
   PubMed Web of Science ®Google Scholar
• Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+ CD25 − Foxp3+T cells in patients with systemic lupus erythematosus. J Immunol. 2009; 182 3: 1689–1695.
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983; 13 3: 227–231.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50 1: 121–127.
   PubMed Web of Science ®Google Scholar
• Wang HY, Wang RF, Regulatory T. cells and cancer. Curr Opin Immunol. 2007; 19 2: 217–223.
   PubMed Web of Science ®Google Scholar
• Venken K. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res. 2006; 83 8: 1432–1446 HellgsNHensenKRummensJLMaerRDHoogheMBDuboisBRausJStissenP.
   PubMed Web of Science ®Google Scholar
• Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res. 2005; 81 1: 45–52.
   PubMed Web of Science ®Google Scholar
• Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, Stinissen P. Natural naive CD4+CD25+CD127 low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. J Immunol. 2008; 180 9: 6411–6420.
   PubMed Web of Science ®Google Scholar
• Fransson ME, Liljenfeldt LS, Fagius J, Totterman TH, Loskog AS. The T-cell pool is anergized in patients with multiple sclerosis in remission. Immunology. 2009; 126 1: 92–101.
   PubMed Web of Science ®Google Scholar
• Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+and CD25 − subpopulations. J Immunol. 2000; 165 6: 3105–3110.
   PubMedGoogle Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299 5609: 1057–1061.
   PubMed Web of Science ®Google Scholar
• Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol. 2004; 16 8: 1189–1201.
   PubMedGoogle Scholar
• Matsui M, Araya S, Wang HY, Matsushima K, Saida T. Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis. J Neurol. 2005; 252 8: 908–915.
   PubMedGoogle Scholar
• Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Wurfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA. 2004; 101 23: 8705–8708.
   PubMed Web of Science ®Google Scholar
• Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol. 2008; 38 2: 576–586.
   PubMedGoogle Scholar
• Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens JL, Medaer R, Hupperts R, Stinissen P. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology. 2008; 123 1: 79–89.
   PubMed Web of Science ®Google Scholar
• O'Connor RA, Anderton SM. Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol. 2008; 193 1–2: 1–11.
   PubMedGoogle Scholar
• Markowitz CE. Interferon-beta: Mechanism of action and dosing issues. Neurology. 2007; 68 24 Suppl 4: S8–S11.
   PubMedGoogle Scholar
• Penton-Rol G, Cervantes-Llanos M, Cabrera-Gomez JA, Alonso-Ramirez R, Valenzuela-Silva C, Rodriguez-Lara R, Montero-Casimiro E, Bello-Rivero I, Lopez-Saura P. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Int Immunopharmacol. 2008; 8 6: 881–886.
   PubMedGoogle Scholar
• Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol. 2008; 45 15: 4008–4019.
   PubMedGoogle Scholar